Biotech Values

[rkrw]

I can't name any products, but I think Merck was a company that didn't bother with AG's. For better or for worse. I'm sure there are plenty of other examples.

With respect to mnta, I think people need to worry about the cart before the horse. Approval rests with the fda and no one can say with any certainty what will happen. But if approved, even if sanofi launches a generic, one big offset is you'd think it lowers the perceived approval risk for something like Copaxone.